Compare PRME & SLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRME | SLI |
|---|---|---|
| Founded | 2019 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 536.4M | 524.3M |
| IPO Year | 2022 | 2011 |
| Metric | PRME | SLI |
|---|---|---|
| Price | $3.02 | $2.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $7.56 | $5.25 |
| AVG Volume (30 Days) | ★ 3.1M | 1.6M |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.18 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,632,000.00 | N/A |
| Revenue This Year | $7.06 | N/A |
| Revenue Next Year | $47.01 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 55.28 | N/A |
| 52 Week Low | $2.67 | $1.91 |
| 52 Week High | $6.94 | $6.40 |
| Indicator | PRME | SLI |
|---|---|---|
| Relative Strength Index (RSI) | 42.71 | 44.52 |
| Support Level | $2.74 | $2.08 |
| Resistance Level | $3.60 | $4.38 |
| Average True Range (ATR) | 0.18 | 0.12 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 46.00 | 85.71 |
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
Standard Lithium Corp is engaged in the exploration and development of lithium brine properties in the United States. The company's flagship projects are located in the Smackover Formation, a world-class lithium brine asset, focused in Arkansas and Texas. It is also Standard Lithium is advancing the South West Arkansas project, a greenfield project located in southern Arkansas, and strengthening lithium brine prospects in East Texas. Its other project comprises the Lanxess Property Project; and California Properties. The technologies used for the projects are : Direct Lithium Extraction; Demonstration Plant; SiFT; Lithium Sulfide; and Aqualung.